- 01Oribiotech signs 10-year, US$120m IRO deal.
- 02AdAlta validates IRO for commercial use.
- 03IRO: 10–50x doses; 30–50% cost cuts.
- 04APAC rollout for AdAlta's pipeline.
AdAlta Limited (ASX: 1AD) has gained commercial validation for the automated manufacturing platform it plans to use across future cellular immunotherapies after partner Oribiotech secured a major long-term customer.
Oribiotech has signed a 10-year agreement worth up to US$120 million with an undisclosed commercial-stage biopharmaceutical company to integrate its IRO platform into manufacturing for an already approved and marketed cell therapy.
AdAlta, Oribiotech, and Australian contract manufacturer Cell Therapies signed a Memorandum of Understanding in April 2026 to deploy IRO in Australia and the Asia Pacific for AdAlta’s cellular immunotherapy pipeline.
The new commercial agreement means AdAlta’s future products developed on IRO are intended to use a platform that has now been selected for commercial manufacturing by a company already producing and selling an approved cell therapy.
Adoption Raises Confidence
Moving an established cell therapy manufacturing process carries regulatory, financial, and operational risk because each patient dose is produced individually from living cells and manufacturing changes require comparability work.
Oribiotech’s new partner has nevertheless committed to moving an existing commercial process onto IRO under a decade-long relationship, providing AdAlta with evidence that the platform can meet requirements beyond early-stage development.
“Nobody takes that decision lightly—it is the highest bar in our industry,” chief executive officer Tim Oldham said.
“It means the cellular immunotherapies we develop on IRO will be made on a platform that our eventual partners have already validated, endorsed, and put into commercial use—taking a significant question off the table in any future partnering conversation.”
AdAlta considers the decision important because its business model relies on partnerships with or sales to larger pharmaceutical companies, which scrutinise manufacturing capability alongside clinical performance when assessing cell therapy assets.
Targeting Scale and Cost
IRO is a fully closed automated system designed to carry a cell therapy manufacturing process from research through to commercial production on a single platform.
The platform is designed to deliver 10 to 50 times more patient doses from the same physical footprint while reducing manufacturing costs by 30% to 50% and lowering variability through automation and digitisation.
AdAlta also expects development on a single platform to make processes easier to scale for commercial manufacture and transfer between manufacturing sites without rebuilding them from the beginning.
These characteristics are intended to address cost, capacity, consistency, and transferability, which AdAlta regards as central considerations in whether cellular immunotherapies can move from clinical trials into larger-scale commercial supply.
Compatibility a Design Priority
AdAlta’s lead cell therapy EW-001 will not be manufactured on IRO because it already has a low-cost, rapid, and scalable manufacturing process that was established before the Oribiotech collaboration.
That manufacturing process is being transferred from Shanghai Cell Therapy Group to Cell Therapies and does not benefit from being moved onto IRO in its current form.
For subsequent products, however, IRO compatibility is now a design priority as AdAlta assesses candidates under its East to West strategy and seeks assets whose manufacturing can be built on the platform from the outset.
Deployment of IRO at Cell Therapies under the April 2026 arrangement is expected to begin once active discussions to license a suitable next product have concluded.
Get the wire before the market opens.
The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.